Erik S. Knudsen

21.3k total citations · 4 hit papers
199 papers, 15.1k citations indexed

About

Erik S. Knudsen is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Erik S. Knudsen has authored 199 papers receiving a total of 15.1k indexed citations (citations by other indexed papers that have themselves been cited), including 156 papers in Oncology, 105 papers in Molecular Biology and 58 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Erik S. Knudsen's work include Cancer-related Molecular Pathways (114 papers), Advanced Breast Cancer Therapies (50 papers) and Microtubule and mitosis dynamics (30 papers). Erik S. Knudsen is often cited by papers focused on Cancer-related Molecular Pathways (114 papers), Advanced Breast Cancer Therapies (50 papers) and Microtubule and mitosis dynamics (30 papers). Erik S. Knudsen collaborates with scholars based in United States, United Kingdom and Australia. Erik S. Knudsen's co-authors include Agnieszka K. Witkiewicz, Karen E. Knudsen, Jean Y. J. Wang, Uzma Asghar, Nicholas C. Turner, Jeffry L. Dean, A. Kathleen McClendon, Matthew W. Strobeck, Alvaro Puga and Adam Ertel and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Erik S. Knudsen

196 papers receiving 14.9k citations

Hit Papers

4 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The history and future of targeting cyclin-dependent kinases in cancer therapy

2015 1.3k citations Agnieszka K. Witkiewicz, Erik S. Knudsen et al. profile →
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets

2015 784 citations Agnieszka K. Witkiewicz, Uthra Balaji et al. Nature Communications profile →
Nucleophosmin/B23 Is a Target of CDK2/Cyclin E in Centrosome Duplication

2000 546 citations Erik S. Knudsen et al. profile →
Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression

2024 75 citations Erik S. Knudsen, Agnieszka K. Witkiewicz et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Erik S. Knudsen United States	68	8.5k	8.4k	4.0k	3.5k	1.7k	199	15.1k
Agnieszka K. Witkiewicz United States	60	6.5k 0.8×	7.0k 0.8×	3.1k 0.8×	5.1k 1.4×	1.5k 0.9×	176	13.6k
Gary E. Gallick United States	67	6.0k 0.7×	7.7k 0.9×	2.0k 0.5×	2.9k 0.8×	1.3k 0.8×	202	13.7k
Elisa de Stanchina United States	65	7.0k 0.8×	13.8k 1.6×	3.0k 0.8×	4.9k 1.4×	855 0.5×	226	19.4k
Joyce M. Slingerland United States	60	8.1k 0.9×	10.3k 1.2×	1.5k 0.4×	3.0k 0.9×	1.9k 1.1×	120	15.5k
Yoshitaka Sekido Japan	69	3.7k 0.4×	9.3k 1.1×	3.6k 0.9×	3.3k 0.9×	1.6k 0.9×	199	14.3k
Andrew Koff United States	53	8.7k 1.0×	10.2k 1.2×	1.6k 0.4×	2.0k 0.6×	2.2k 1.3×	103	15.0k
Weiya Xia United States	56	8.0k 0.9×	12.4k 1.5×	1.8k 0.5×	3.8k 1.1×	1.3k 0.7×	114	18.0k
Ju‐Seog Lee United States	61	3.7k 0.4×	7.9k 0.9×	2.2k 0.5×	3.9k 1.1×	1.6k 0.9×	218	13.3k
Leif W. Ellisen United States	54	4.9k 0.6×	9.4k 1.1×	1.6k 0.4×	3.9k 1.1×	1.1k 0.6×	152	15.9k
Tatsuhiro Shibata Japan	60	4.6k 0.5×	8.3k 1.0×	4.2k 1.0×	3.8k 1.1×	470 0.3×	202	15.0k

Countries citing papers authored by Erik S. Knudsen

Since Specialization

Citations

This map shows the geographic impact of Erik S. Knudsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik S. Knudsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik S. Knudsen more than expected).

Fields of papers citing papers by Erik S. Knudsen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik S. Knudsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik S. Knudsen. The network helps show where Erik S. Knudsen may publish in the future.

Co-authorship network of co-authors of Erik S. Knudsen

This figure shows the co-authorship network connecting the top 25 collaborators of Erik S. Knudsen. A scholar is included among the top collaborators of Erik S. Knudsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik S. Knudsen. Erik S. Knudsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kumarasamy, Vishnu, Michelle Roti, John Bisi, et al.. (2025). Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle. Nature Communications. 16(1). 1476–1476. 8 indexed citations

Wu, Jin, et al.. (2024). Separable Cell Cycle Arrest and Immune Response Elicited through Pharmacological CDK4/6 and MEK Inhibition in RASmut Disease Models. Molecular Cancer Therapeutics. 23(12). 1801–1814. 3 indexed citations

Knudsen, Erik S., Emily Schultz, Kristopher Attwood, et al.. (2022). Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2− Breast Cancer at a Single Cancer Center. The Oncologist. 27(8). 646–654. 20 indexed citations

Gandhi, Shipra, Manu Pandey, Kristopher Attwood, et al.. (2020). Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity. Clinical Cancer Research. 27(1). 87–95. 87 indexed citations

Knudsen, Erik S., Vishnu Kumarasamy, Sejin Chung, et al.. (2020). Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer. Gut. 70(1). 127–138. 59 indexed citations

Kumarasamy, Vishnu, Paris Vail, Ram Nambiar, Agnieszka K. Witkiewicz, & Erik S. Knudsen. (2020). Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition. Cancer Research. 81(5). 1347–1360. 42 indexed citations

Guiley, Keelan Z., Kevin Lou, Krister J. Barkovich, et al.. (2019). p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition. Science. 366(6471). 154 indexed citations

Balaji, Uthra, et al.. (2018). Sensitive and specific post-call filtering of genetic variants in xenograft and primary tumors. Bioinformatics. 34(10). 1713–1718. 2 indexed citations

Chung, Sejin, Paris Vail, Agnieszka K. Witkiewicz, & Erik S. Knudsen. (2018). Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer. Clinical Cancer Research. 25(7). 2290–2304. 26 indexed citations

10.

Jansen, Valerie M., Neil E. Bhola, Joshua A. Bauer, et al.. (2017). Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. Cancer Research. 77(9). 2488–2499. 171 indexed citations

11.

Knudsen, Erik S., Paris Vail, Uthra Balaji, et al.. (2017). Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers. Clinical Cancer Research. 23(15). 4429–4440. 143 indexed citations

12.

Hutcheson, Jack, Uthra Balaji, Matthew R. Porembka, et al.. (2016). Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease. Clinical Cancer Research. 22(14). 3606–3617. 65 indexed citations

13.

Witkiewicz, Agnieszka K., Uthra Balaji, & Erik S. Knudsen. (2014). Systematically Defining Single-Gene Determinants of Response to Neoadjuvant Chemotherapy Reveals Specific Biomarkers. Clinical Cancer Research. 20(18). 4837–4848. 15 indexed citations

14.

Dean, Jeffry L., A. Kathleen McClendon, Theresa E. Hickey, et al.. (2012). Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle. 11(14). 2756–2761. 182 indexed citations

15.

Witkiewicz, Agnieszka K., Dayana B. Rivadeneira, Adam Ertel, et al.. (2011). Association of RB/p16-Pathway Perturbations with DCIS Recurrence. American Journal Of Pathology. 179(3). 1171–1178. 41 indexed citations

16.

Li, Zhiping, Xuanmao Jiao, Chenguang Wang, et al.. (2010). Alternative Cyclin D1 Splice Forms Differentially Regulate the DNA Damage Response. Cancer Research. 70(21). 8802–8811. 94 indexed citations

17.

Kuwahara, Yasumichi, Aubri Charboneau, Erik S. Knudsen, & Bernard E. Weissman. (2010). Reexpression of hSNF5 in Malignant Rhabdoid Tumor Cell Lines Causes Cell Cycle Arrest through a p21CIP1/WAF1-Dependent Mechanism. Cancer Research. 70(5). 1854–1865. 37 indexed citations

18.

Fan, Yunxia, Gregory P. Boivin, Erik S. Knudsen, et al.. (2009). The Aryl Hydrocarbon Receptor Functions as a Tumor Suppressor of Liver Carcinogenesis. Cancer Research. 70(1). 212–220. 149 indexed citations

19.

Koller, Erich, et al.. (2008). Stress and IGF-I Differentially Control Cell Fate through Mammalian Target of Rapamycin (mTOR) and Retinoblastoma Protein (pRB). Journal of Biological Chemistry. 283(42). 28265–28273. 18 indexed citations

20.

Sharma, Ankur, Clay E.S. Comstock, Erik S. Knudsen, et al.. (2007). Retinoblastoma Tumor Suppressor Status Is a Critical Determinant of Therapeutic Response in Prostate Cancer Cells. Cancer Research. 67(13). 6192–6203. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact